The Thoracic Alliance for Cancer Trials

November 2016
There is a significant unmet need in lung cancer research

- Lung cancer is both the most common cancer and the greatest cause of cancer death globally
- Outcomes remain poor with 5-year relative survival of only 14% in countries with the best outcomes
- For patients with advanced incurable disease, there have been major recent advances in EGFR and ALK mutated cancer
- Many more targeted therapies as well as immunotherapies are showing impressive results
A global effort will address key clinical research challenges

- Trials requiring very large numbers of patients
e.g. Adjuvant trials post-surgery

- Multimodality therapy
e.g. Stage III NSCLC

- Rare molecular subgroups
e.g. Adjuvant TKI following surgery for Alk+ NSCLC

- Rare thoracic malignancies
  Thymic tumours, mesothelioma
History of TACT

• ASCO 2014 in-principle agreement to establish an international cooperative group for thoracic oncology research
• Steering committee formed
• Seed funding secured
  – Lung Foundation Australia, Australasian Lung Cancer Trials Group, industry
• Development Officer recruited
• Dialogue with multinational cooperative groups to evaluate different models
  – Gynaecological Cancer Intergroup (GCIG)
  – Breast International Group (BIG)
• TACT formally established with Board and Membership Working Group September 2015 at 16th WCLC
  – Legal entity: Lung Foundation Australia
  – Secretariat: Brisbane, QLD Australia
More than 25 groups involved to date

NCRI
British Thoracic Oncology Group

Korean Cancer Study Group
Korean Lung Cancer Consortium

JSMO
West Japan Oncology Group

CSCO
Chinese Thoracic Oncology Group

Taiwan Lung Cancer Clinical Trial Consortium

Indian Co-Operative Oncology Network
India – Lung Cancer Consortium

TACT
THORACIC ALLIANCE FOR CANCER TRIALS
Mission and aims

An international non-profit umbrella organisation for academic research groups from around the world, dedicated to facilitating thoracic oncology research

• Facilitate and promote international research collaboration in thoracic cancer
• Provide a platform to conduct clinical trials requiring multiple groups
• Combine resources and expertise to conduct research more efficiently and reduce duplication of effort
• Allow trials to recruit more quickly
• Establish clinical and translational research priorities
Operating principles

- Mutual respect and equity for individuals, cultures and nations
- A strong sense of common purpose
- Providing new opportunities for all members; not replicating an existing group
- Facilitating, supporting and serving as a mechanism to advance the intellectual contributions of individuals and member groups
- Independence from the pharmaceutical/ biotechnology industry, even if trials are industry-sponsored
- Adherence to Good Clinical Practice guidelines and applicable laws
- An agreed set of rules to support fair and efficient processes within the group
Activities

• Build on existing international relationships
• Develop and conduct trials which require large numbers of patients and/or where accrual is difficult
  – Including multi-modality therapy and rare thoracic malignancies or subtypes
• Conduct translational research
• Collaborate with other scientific networks
• Develop models of collaboration with the pharmaceutical and biotechnology industry that preserve scientific independence
• Promote other academic thoracic oncology activities
Board membership reflects TACT’s global network

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Mitchell (Chair)</td>
<td>ALTG</td>
<td>Australia/NZ</td>
</tr>
<tr>
<td>Glen Goss</td>
<td>NCIC-CTG</td>
<td>Canada</td>
</tr>
<tr>
<td>Rebecca Heist</td>
<td>Alliance</td>
<td>USA</td>
</tr>
<tr>
<td>Karen Kelly</td>
<td>SWOG</td>
<td>USA</td>
</tr>
<tr>
<td>Bartomeu Massuti</td>
<td>GECP</td>
<td>Spain</td>
</tr>
<tr>
<td>Tony Mok</td>
<td>Asia/IASLC</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Marianne Nicolson</td>
<td>NCRI-CSG</td>
<td>UK</td>
</tr>
<tr>
<td>Mary O’Brien</td>
<td>EORTC</td>
<td>Europe</td>
</tr>
<tr>
<td>Ken O’Byrne</td>
<td>ALTG/ETOP</td>
<td>Australia/NZ &amp; Europe</td>
</tr>
<tr>
<td>Nick Pavlakis</td>
<td>ALTG</td>
<td>Australia/NZ</td>
</tr>
<tr>
<td>Suresh Ramalingam</td>
<td>ECOG</td>
<td>USA</td>
</tr>
<tr>
<td>Rolf Stahel</td>
<td>ETOP/SAKK</td>
<td>Europe/Switzerland</td>
</tr>
<tr>
<td>Virginie Westeel</td>
<td>IFCT</td>
<td>France</td>
</tr>
</tbody>
</table>
Board membership reflects TACT’s global network
13 member groups

- BTOG (observer)
- Cancer Trials Ireland
- Alliance
- ECOG
- SWOG
- IFCT
- ETOP
- GECP
- CECOG
- APRIC
- ALTG
- TROG
- JCOG
Board priorities

• Establish the structure
• Demonstrate capabilities
• Develop documentation to support governance and operations
• Build awareness and establish relationships
Full structure in place 2018 (est.)

Board

Standing Committees
- Board Executive & Finance
- Nominations
- Membership
- NSCLC early
- NSCLC advanced
- Small cell, mesothelioma & rare tumours

Working Groups
- Molecular profiling & translational research
- Harmonisation

General Assembly (Member Reps)
2015-2018 – a transition phase

• Twice-yearly member meetings at ASCO and WCLC
  – 2016  ASCO Chicago (June 3)  WCLC Vienna (Dec 4)
  – 2017  ASCO Chicago  WCLC Yokohama (Oct)
  – 2018  ASCO Chicago  WCLC Toronto (Nov)

• Quarterly Board and Working Group teleconferences

• Fully democratic structure in three years
  – Board members formally voted in by the General Assembly
  – Appointed Standing Committees and Working Groups
  – General Assembly will discuss trial proposals
Industry partners

Celgene
Boehringer Ingelheim
Bristol-Myers Squibb
AstraZeneca

TACT
THORACIC ALLIANCE FOR CANCER TRIALS
Welcome to the website of TACT, the Thoracic Alliance for Cancer Trials. TACT is a unique opportunity to improve outcomes for patients with thoracic malignancy by facilitating clinical research through a truly global network, harmonisation of governance and operations and fostering a genuine collaboration among groups and with external partners. TACT was established in September 2015 at the 16th World Conference on Lung Cancer in Denver, Colorado as an international non-profit umbrella organisation for worldwide academic groups who are dedicated to thoracic oncology research. With our global reach, TACT is ideally positioned to navigate the increasingly complex landscape of lung cancer diagnosis and novel treatment approaches by enabling lung cancer researchers worldwide to work together on joint projects and clinical trials.

Paul Mitchell, Board Chair

**TACT Development Officer**
c/o Lung Foundation Australia
PO Box 1949
Milton QLD 4064
Australia

T: +61 (0) 7 3251 3600
M: +61 (0) 481 394 982
F: +61 (0) 7 3368 3564
E: enquiries@tacllung.com
Summary

• TACT is a unique opportunity to improve the outcomes of patients with thoracic malignancy by facilitating clinical research

• The group intends to learn from and adapt the best elements of other collaborative group efforts to date
  – Truly global membership
  – Key governance and operational elements in place from “go”
  – A genuine collaboration among groups and with external partners